Entrada Therapeutics, Inc. (NasdaqGM: TRDA)
Health Care · Biotechnology · US
$7.62
+0.66% today · +34.5% 1Y
Entrada Therapeutics, Inc. (NasdaqGM: TRDA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $272.95M and employs 152 people.
Over the last twelve months the share price has gained 34.5%, trading between 5.02 and 16.45.
Tweenvest scores Entrada Therapeutics, Inc. across four factors: quality 44/100, value 45/100. Its strongest factor is value.
TRDA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $272.95M
- Revenue (TTM)
- $4.69M
- P/E
- —
- EPS
- -3.97
- Dividend yield
- —
- Beta (5Y)
- -0.26
- 52-week high
- $16.45
- 52-week low
- $5.02
- Avg volume (3M)
- —
- Shares outstanding
- 36.06M
- Employees
- 152
- Next earnings
- —
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
- ISIN
- US29384C1080
- Founded
- 2016
- Listed since
- Oct 29, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.